0000899243-18-019319.txt : 20180703
0000899243-18-019319.hdr.sgml : 20180703
20180703183708
ACCESSION NUMBER: 0000899243-18-019319
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180702
FILED AS OF DATE: 20180703
DATE AS OF CHANGE: 20180703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FORMELA JEAN FRANCOIS
CENTRAL INDEX KEY: 0001030575
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 18938902
MAIL ADDRESS:
STREET 1: C/O ATLAS VENTURE
STREET 2: 890 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-07-02
0
0001693415
Translate Bio, Inc.
TBIO
0001030575
FORMELA JEAN FRANCOIS
C/O TRANSLATE BIO, INC.
29 HARTWELL AVENUE
LEXINGTON
MA
02421
1
0
0
0
Common Stock
2018-07-02
4
C
0
3832010
A
3922010
I
By Atlas Venture Fund VIII, L.P.
Series A Preferred Stock
2018-07-02
4
C
0
12925244
0.00
D
Common Stock
2326567
0
I
By Atlas Venture Fund VIII, L.P.
Series B Preferred Stock
2018-07-02
4
C
0
5838230
0.00
D
Common Stock
1050891
0
I
By Atlas Venture Fund VIII, L.P.
Series C Preferred Stock
2018-07-02
4
C
0
2525253
0.00
D
Common Stock
454550
0
I
By Atlas Venture Fund VIII, L.P.
The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
These shares are held directly by Atlas Venture Fund VIII, L.P. ("Atlas Venture Fund VIII"). The sole general partner of Atlas Venture Fund VIII is Atlas Venture Associates VIII, L.P. ("AVA VIII LP"). Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ Frank Castellucci, as attorney-in-fact for Jean-Francois Formela
2018-07-03